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Abstract
Background: To identify predictors of prolonged or shortened progression-free survival (PFS) and overall survival
(OS) among patients with metastatic renal cell carcinoma (mRCC) who received first-line targeted therapies.
Methods: This retrospective study included 146 patients with mRCC who were treated during 2007–2015. These
patients were divided into a group with the worst response (WG), an expected group (EG), and a group with the
best response (BG), based on their PFS (≤3 monthsnths, 3–18 monthsnths, and >18 monthsnths, respectively) and
OS (<1 year, 1–3 years, and >3 years, respectively). To identify significant predictive factors, the BG and WG were
compared to the EG using the Memorial Sloan Kettering Cancer Center and Heng risk models.
Results: The overall PFS and OS were 9.3 months and 16.4 months, respectively. The median PFS for the WG (41.8 %),
EG (45.9 %), and BG (12.3 %) were 2.7 months, 9.3 months, and 56.6 months, respectively, and the median OS for the WG
(45.9 %), EG (35.6 %), and BG (18.5 %) were 5.5 months, 21.6 months, and 63.1 months, respectively; these outcomes
were significantly different (p < 0.001). Nephrectomy (odds ratio [OR]: 7.15) was a significant predictor of PFS in the BG,
and the significant predictors of OS in the BG were MSKCC intermediate risk (OR: 0.12), poor risk (OR: 0.04), and a disease-
free interval of <1 year (OR: 0.23) (all, p < 0.05). Anemia (OR: 3.25) was a significant predictor of PFS in the WG, and the
significant predictors of OS were age (OR: 1.05), anemia (OR: 4.13), lymphocytopenia (OR: 4.76), disease-free interval of
<1 year (OR: 4.8), and synchronous metastasis (OR: 3.52) (all, p < 0.05).
Conclusion: We identified several significant predictors of unexpectedly good and poor response to first-line targeted
therapy among patients with mRCC.
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Background
Research regarding the molecular biology of renal cell car-
cinoma (RCC) and the subsequent introduction of tar-
geted therapeutic agents (TTs) have resulted in improved
treatment guidelines for metastatic RCC (mRCC), and sig-
nificantly improved progression-free survival (PFS) and
overall survival (OS) [1, 2]. However, the appropriate treat-
ment for mRCC in each case remains unclear, as the tu-
mor’s heterogeneity can affect the clinical outcomes after
TT treatment, and it is difficult to accurately predict indi-
vidual patients’ prognoses. Therefore, it remains challen-
ging to optimize therapeutic outcomes using personalized
therapy.
Diverse criteria are used to stratify patients’ prognoses,
evaluate therapeutic responses, and determine patients’ eli-
gibility for TTs, and these criteria are used to help predict
the patients’ PFS and OS after TT treatment [3, 4]. Among
the various evaluation tools and prognostic models, the
RECIST criteria [5] are the best known and most com-
monly used evaluation tools for radiologically stratifying pa-
tients with solid tumors who received TT treatment, based
on the responses of their primary tumor and metastatic le-
sions [4, 6]. Furthermore, the Memorial Sloan Kettering
Cancer Center (MSKCC) [7, 8] and the International Meta-
static Renal Cell Carcinoma Database Consortium (IMDC,
also named as Heng) risk criteria [9] have been used in clin-
ical prognostic models that predict the response to TT
among patients with mRCC. However, even with these
tools, clinicians may encounter difficulties in identifying pa-
tients who might experience clinical outcomes that signifi-
cantly deviate from the expected outcomes. Therefore, the
present study aimed to evaluate the clinicopathological
characteristics of patients with mRCC who experience un-
expectedly prolonged or shortened PFS and OS, and to
identify significant predictors of unexpected clinical re-
sponses to first-line TTs.
Methods
This retrospective study was approved by the institutional
review board of the Research Institute and Hospital Na-
tional Cancer Center (approval no. NCC2014-0155), and
the requirement for informed consent was waived. All pa-
tient data were anonymized and de-identified prior to our
analysis. All study protocols were performed in accord-
ance with the ethical tenets of the Declaration of Helsinki.
We identified 146 patients with mRCC and an intact
contralateral kidney, who were treated using first-line
TTs without any prior systemic treatment between Janu-
ary 2007 and April 2015. All included patients had
complete follow-up and medical history data, and none
of the patients discontinued their first-line TT due to
Grade 3 or higher adverse events. The specific first-line
TT was selected at the discretion of the treating urolo-
gist (JC), who considered each patient’s histopathology,
disease status, medical condition, and the wishes of the pa-
tient and their family after a comprehensive discussion re-
garding the anticipatory efficacy and adverse events of each
TT. Each cycle of sunitinib consisted of a daily 50-mg oral
dose over a 4-week period, which was followed by a 2-week
hiatus. Each cycle of sorafenib consisted of twice-daily 400-
mg oral doses for a 6-week period. Each cycle of pazopanib
consisted of a daily 800-mg oral dose over a 6-week period.
Each cycle of temsirolimus consisted of a weekly 25-mg
intravenous infusion over a 6-week period. All patients
underwent a complete evaluation after every two cycles of
TT, which included a total physical evaluation, blood tests,
and radiological examinations. The radiological examina-
tions included contrast-enhanced computed tomography
and/or positron emission tomography–computed tomog-
raphy and bone scans to evaluate treatment response,
which was based on the RECIST criteria (version 1.1) [5].
Treatment was continued until disease progression was
identified.
The 146 patients were grouped according to their PFS
and OS, and the cut-offs were selected based on previ-
ously published representative findings that included a
PFS of 4–18.8 months and an OS of 11.9–33.1 months
[1, 2, 10–12]. Therefore, to stratify patients as having ex-
perienced unexpectedly prolonged or shortened OS and
PFS, we categorized the patients using PFS cut-offs of
3 months and 18 months, and OS cut-offs of 1 year and
3 years. The upper PFS cut-off value was not set to
17 months, as none of the patients exhibited a PFS of ap-
proximately 17 months during their first-line TT treatment.
Thus, the patients were grouped according to whether they
had experienced the worst survival outcomes (WG; PFS:
≤3 months, OS: <1 year), the normally expected outcomes
(EG; PFS: 3–18 months, OS: 1–3 years), or the best survival
outcomes (BG; PFS: >18 months, OS: >3 years).
Differences and associations between the baseline charac-
teristics were examined using the chi-square test, Fisher’s
exact test, and the Kruskal-Wallis test, as appropriate. Bin-
ary logistic regression models were used to calculate the
odds ratios (ORs) and 95 % confidence intervals (CIs) for
the factors that significantly affected the BG and WG out-
comes, compared to the EG outcomes. Only factors with a
p-value of <0.10 in the univariable analysis were subse-
quently evaluated in the multiple logistic regression ana-
lysis, using backwards stepwise selection with a significance
level of 0.10. Variables with large amounts of missing data
(>20 % of patients) were excluded from the multivariable
analysis (clinical T and N stages, and pathological T, N,
and M stages). The times to progression and death
were evaluated using Kaplan-Meier curves and the log-
rank test. All analyses were performed using Stata soft-
ware (version 13.1; Stata Corp., College Station, TX,
USA), and differences with a p-value of <0.05 were con-
sidered statistically significant.
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Table 1 Clinicopathological characteristics of the worst group (n = 61, 41.8 %), expected group (n = 67, 45.9 %), and the best group
(n = 18, 12.3 %), according to their progression-free survival
Variables (N, %) Worst Group (≤3 mo) Control Group (>3 and ≤18 mo) Best Group (>18 mo) p-value
Age 58.5 ± 10.9 58.0 ± 11.2 60.5 ± 11.1 0.697
Gender Male/Female 45/1 (73.8/26.2) 55/12 (82.1/37.7) 17/1 (94.4/5.6) 0.140
Body mass index (kg/m2) 23.4 ± 3.1 23.2 ± 2.7 23.9 ± 2.0 0.647
MSKCC criteria <0.001
Favorable 3 (5.9) 5 (9.3) 6 (37.5)
Intermediate 30 (58.8) 42(77.8) 10 (62.5)
Poor 18 (35.3) 7 (13.0) 0
Heng criteria 0.003
Favorable 5 (8.9) 9 (15.8) 8 (47.1)
Intermediate 38 (67.9) 42 (73.7) 9 (52.9)
Poor 13 (23.2) 6 (10.5) 0
ECOG 0 54 (93.1) 59 (100) 18 (100) 0.078
1 4 (6.9) 0 0
Metastatic site
Lung 48 (80.0) 57 (89.1) 14 (77.8) 0.268
Liver 15 (25.0) 9 (14.8) 1 (5.9) 0.139
Lymph node 32 (53.3) 31 (49.2) 9 (50.0) 0.918
Bone 19 (32.2) 21 (34.4) 6 (35.3) 0.968
Brain 7 (11.7) 7 (11.7) 2 (12.5) 1.000
Other metastasis 13 (22.0) 12 (19.7) 2 (11.8) 0.691
Nephrectomy 28 (45.9) 35 (52.2) 16 (88.9) 0.004
Embolization 3 (4.9) 3 (4.5) 2 (11.1) 0.455
Clinical T stage 0.371
T1 7 (16.3) 5 (10.7) 2(16.7)
T2 4 (9.3) 11(23.4) 0
T3 22 (51.1) 15 (32.0) 3 (25.0)
T4 3 (7.0) 6(12.8) 3 (25.0)
Tx 7(16.3) 10 (21.3) 4 (33.3)
N1 9 (18.8) 9 (19.1) 4 (28.6) 0.570
synchronous metastasis 35 (59.3) 50 (75.8) 12 (66.7) 0.144
Fuhrman nuclear grade 0.767
1–2 14 (34.1) 8 (36.7) 3 (25.0)
3–5 27 (65.9) 31 (63.3) 9 (75.0)
Histology 0.701
Clear cell type 45 (77.6) 55(87.3) 11 (73.3)
Non-clear cell type 2(3.4) 1 (16) 0
Chromophobe with clear cell 2 (3.3) 3 (4.5) 1 (5.6)
Papillary with clear cell 7 (12.2) 2 (3.5) 2 (14.4)
unknown type 2 (3.4) 2 (3.2) 1(6.7)
Sarcomatoid presence 5(8.8) 4 (6.5) 1 (6.7) 0.895
Treatment 0.877
Sunitinib 43 (70.5) 45 (67.2) 13 (72.2)
Sorafenib 8(13.1) 8 (11.9) 1 (5.6)
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Results
The disease control rate, objective response rate, PFS, and
OS among all 146 patients were 70.6 %, 46.3 %, 9.3 months
(95 % CI: 7.3–11.2 months), and 16.4 months (95 % CI:
12.2–20.8 months), respectively. Seven patients (6.4 %)
achieved complete response, 15 patients (10.3 %) were still
being treated with first-line TT (i.e., stable disease or partial
response), and 105 patients (71.9 %) exhibited a
progression-free interval of <1 year. The baseline character-
istics of the patients in the WG, EG, and BG are summa-
rized in Tables 1 and 2. The median PFS for the WG (n =
61, 41.8 %), EG (n = 67, 45.9 %), and BG (n = 18, 12.3 %)
were 2.7 months (95 % CI: 2.4–2.9 months), 9.3 months
(95 % CI: 8.3–11.1 months), and 56.6 months (95 % CI:
22.4–68.4 months), respectively (Fig. 1a). The median OS
of the WG (n = 65, 45.9 %), EG (n = 52, 35.6 %), and BG (n
= 27, 18.5 %) were 5.5 months (95 % CI: 4.5–6.9 months),
21.6 months (95 % CI: 19.8–24.4 months), and 63.1 months
(95 % CI: 44.3–75.4), respectively (Fig. 1b). These survival
outcomes were significantly different (all, p < 0.001).
The correlation and parametric trend tests for PFS and
OS revealed that each group’s PFS and OS were signifi-
cantly correlated (Pearson’ correlation coefficient: 0.6283,
and non-parametric trend test, p < 0.001). The correlation
percentages for the BG, EG, and WG were 50 % (n = 9,
PFS: >18 months, OS: >3 years), 49.3 % (n = 33, PFS: 3–
18 months, OS: 1–3 years), and 72.1 % (n = 44, PFS:
≤3 months, OS: <1 year).
When we compared the BG and EG using the complete
MSKCC risk evaluation, only nephrectomy (OR: 7.15,
95 % CI: 1.43–35.67) was a significant predictor of PFS in
the multivariate analysis (p = 0.016) (Table 3, see also
Additional file 1: Table S1). The significant predictors of
OS were MSKCC intermediate risk (OR: 0.12, 95 % CI:
0.003–0.049), MSKCC poor risk (OR: 0.04, 95 % CI: 0.01–
0.87), and a disease-free interval of <1 year (Heng, OR:
0.23, 95 % CI: 0.07–0.73) (all, p < 0.05) (Table 4, see also
Additional file 1: Table S2).
When we compared the WG (n = 105) and EG (n = 113),
the only significant predictor of PFS was anemia (MSKCC,
OR: 3.25, 95 % CI: 1.41–7.52; Heng, OR: 2.87, 95 % CI:
1.23–6.66; both, p < 0.05) (Table 5, see also Additional file 1:
Table S3). The significant predictors of OS were age
(MSKCC, OR: 1.05, 95 % CI: 1.01–1.1), anemia (MSKCC,
OR: 4.13, 95 % CI: 1.44–11.8; Heng, OR: 4.61, 95 % CI:
1.68–12.66), lymphocytopenia (MSKCC, OR: 4.76, 95 % CI:
1.25–18.17; Heng, OR: 5.26, 95 % CI: 1.44–19.14), a
disease-free interval of <1 year (MSKCC, OR: 4.8, 95 % CI:
1.1–20.9), and synchronous metastasis (MSKCC, OR: 3.52,
95 % CI: 1.07–11.61) (all, p < 0.05) (Table 6, see also
Additional file 1: Table S4).
Discussion
The shift to TTs for treating mRCC has greatly improved
the PFS of patients with mRCC. However, TTs are rarely
curative and therapeutic resistance develops after 6–11
Table 1 Clinicopathological characteristics of the worst group (n = 61, 41.8 %), expected group (n = 67, 45.9 %), and the best group
(n = 18, 12.3 %), according to their progression-free survival (Continued)
Pazopanib 8 (13.1) 13(19.4) 4 (22.2)
Temsirolimus 2 (3.3) 1 (1.5) 0
RECIST response <0.001
CR 0 2 (3.3) 5 (29.4)
PR 2 (6.5) 27 (44.3) 8 (47.1)
SD 7 (22.6) 23 (37.7) 3 (17.6)
PD 22 (71.0) 19 (14.8) 1 (5.9)
Laboratory findings
Leukocytosis/Leucopenia 15/0 (26.3/0) 8/3(13.8/5.2) 2/1(11.8/5.9) 0.140
Anemia 43 (75.4) 28 (48.3) 5 (29.4) <0.001
Thrombocytosis/penia 11/2(19.3/3.5) 7/2 (12.1/3.4) 0/0 0.279
Neutrophilia/penia 14/0 (24.6/0) 7/1(12.1/1.7) 1/1 (5.9/5.9) 0.089
Lymphocytosis/penia 2/27 (3.5/47.4) 5/14 (8.6/24.1) 1/1 (5.9/5.9) 0.004
Hyper/hypocalcemia 3/11 (5.3/19.3) 3/3 (5.2/5.2) 0/0 0.059
Hypoalbuminemia 12 (20.3) 0 0 <0.001
LDH elevated 8 (14.0) 4 (6.9) 0 0.190
Neutrophil percent high/low 113 (19.3/5.3) 5/7 (8.6/12.1) 1/5 (5.9/29.4) 0.046
Progression-free survival (mo.) 2.7 (0.1–3.0) 9.3 (3.3–16.5) 56.6 (18.3–68.4) <0.001
Overall survival (mo.) 6.9 (0.3–58.4) 18.6 (4.0–70.3) 68.3 (18.3–78.4) <0.001
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Table 2 Clinicopathological characteristics of the worst group (n = 67, 45.9 %), expected group (n = 52 35.6 %), and best group
(n = 27, 18.5 %), according to their overall survival
Variables (N, %) Worst Group (<1 y) Control Group (1–3 y) Best Group (>3 y) p-value
Age (years) 60.5 ± 10.7 57.1 ± 11.5 56.3 ± 10.3 0.136
Gender (Male/Female) 50/17 (74.6/25.4) 45/7 (86.5/13.5) 22/5 (81.5/18.5) 0.266
Body mass index (kg/m2) 22.9 ± 2.8 23.7 ± 2.5 24.3 ± 2.9 0.096
MSKCC criteria 59 (88.1) 43 (100) 19 (73.1) <0.001
Favorable risk 0 4 (9.3) 10 (52.6)
Intermediate risk 39 (66.1) 34 (79.1) 9 (47.4)
Poor risk 20(33.9) 5 (11.6) 0
Heng criteria 64 (95.5) 44 (84.6) 22 (81.5) <0.001
Favorable risk 2 (3.1) 9(20.5) 11 (50.0)
Intermediate risk 46 (71.9) 32 (72.7) 11 (50.0)
Poor risk 16 (25.0) 3 (6.8) 0
ECOG 0 61(93.8) 47 (100) 23(100) 0.109
1 4 (6.2) 0 0
Metastatic site
Lung 54 (81.8) 42(84.0 23 (88.5) 0.738
Liver 18(27.3) 6 (12.2) 1 (4.3) 0.020
Lymph node 33 (49.3) 17 (36.2) 8 (33.3) 0.064
Bone 23 (34.8) 16 (34.0) 6 (25.0) 0.612
Brain 9 (13.6) 5 (10.6) 2 (8.3) 0.758










Clinical T stage 43 (64.2) 35 (67.3) 0.179
T1 4 (10.8) 6 (17.2) 3 (18.8)
T2 3 (8.1) 8(20.0) 7 (12.5)
T3 15 (40.5) 11 (31.5) 9 (31.3)
T4 8 (21.6) 3 (8.6) 0 (18.8)
Tx 7 (18.9) 7 (20.0) 2(18.8)
N1 13 (31.0) 6 (14.6) 5 (29.4) 0.229
Synchronous metastasis 58(87.9) 31 (60.8) 8 (30.8) 0.001
Fuhrman nuclear grade 41 (61.2) 39 (75.0) 22 (81.5) 0.460
1–2 13 (31.7) 12 (30.8) 10 (45.5)
3–5 28 (68.3) 27 (69.2) 12 (54.5)
Histology 63 (94.0) 50 (96.2) 26 (96.3) 0.581
Clear cell type 50 (79.4) 44 (89.8) 17 (70.8)
Non-clear cell type 2 (3.2) 1 (2.0) 0
Chromophobe with clear cell 2 (3.0) 2 (3.8) 2 (7.4)
Papillary with clear cell 7 (6.5) 1 (2.3) 3 (5.1)
Unknown type 2 (3.2) 1 (2.0) 2 (8.3)
Sarcomatoid presence 3 (4.8 1 (2.0) 2(8.3) 0.168
Treatment 0.430
Sunitinib 42 (62.7) 37 (71.2) 22(81.5)
Sorafenib 9 (13.4) 6 (11.5) 2 (7.4)
Pazopanib 13 (19.4) 9 (17.3) 3 (11.1)
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months of first-line TT treatment, which eventually leads
to disease progression within 4–18.8 months; thus, only a
few studies have reported significant improvements in OS
[1, 2, 10, 11]. However, the absence of any significant im-
provements in OS are mainly related to the confounding ef-
fects of crossover to active treatment from the placebo/
comparator arm. [13] Nevertheless, TT resistance and dis-
ease control are addressed via sequential therapy using vari-
ous combinations of TTs, which provide a general OS of
11.9–33.1 months, and an OS of 9.0–10.9 months for pa-
tients with poor-risk features [9, 10, 12, 14, 15].
In the present study, we used PFS cut-off values of
3 months and 18 months, and OS cut-off values of 1 year
and 3 years, in order to identify the patients that experi-
enced unexpectedly prolonged or shortened survival out-
comes [1, 2, 10, 12]. The cut-off for unexpectedly prolonged
PFS was selected based on a review of sorafenib and suniti-
nib by Porta et al. [13], and a study by Buchler et al. that re-
ported a PFS of 17.7 months among patients who received
sunitinib followed by sorafenib (n = 138), and 18.8 months
among patients who received sorafenib followed by suniti-
nib (n = 122) [16]. Another review article [12] reported that
a study of sorafenib from the Nexavar Charity Patient Aid
Program provided a PFS of 17.6 months with a 95 % disease
control rate. The OS cut-off was supported by data from
the SWITCH study, which reported an OS of 31.5 months
for the sorafenib-sunitinib group and an OS of 30.2 months
for the sunitinib-sorafenib group [17]. Furthermore, Tomita
et al. reported that their first-line TT group (n = 25, a
median of six 6-week cycles) achieved an OS of 33.1 months,
and their pretreated group (n = 26; 9.5 cycles of TT)
achieved an OS of 32.5 months [12]. Therefore, we com-
pared the correlations between PFS and OS in each group,
and found that these outcomes were well correlated. Inter-
estingly, the WG exhibited the greatest correlation between
PFS and OS (72.1 % of patients), while the BG and EG only
exhibited correlations for 50 % of their patients.
In the present study, the overall disease control rate
(70.6 %), objective response rate (46.3 %), and median PFS
(9.3 months, 95 % CI: 7.3–11.2 months) were similar to
those of other previously published series (69–79 %,
24–32 %, and PFS: 5.5–11.1 months for first-line suniti-
nib [11, 18], sorafenib [11, 19, 20], and pazopanib [21],
respectively). In contrast, the median OS (16.4 months,
95 % CI: 12.2–20.8 months) was shorter than those in pre-
vious TT trials (22.9–26.4 months) [10, 12, 13]. This dis-
crepancy may be related to the fact that the previous
studies generally included patients who had undergone
nephrectomy and exhibited clear cell histology, while the
present study included relatively small proportions of pa-
tients who had undergone nephrectomy (54.1 %), exhib-
ited sarcomatoid histology (6.8 %), exhibited non-clear cell
histology (18.4 %), or had poor- or unknown-risk features
(30.0–34.2 %) according to the MSKCC and Heng criteria.
Our multivariate analyses revealed that nephrectomy
(MSKCC, HR: 7.15) was the only significant predictor of
PFS in the BG, and that anemia (MSKCC, HR: 3.25; Heng,
HR: 2.87) was the only significant predictor of PFS in the
Table 2 Clinicopathological characteristics of the worst group (n = 67, 45.9 %), expected group (n = 52 35.6 %), and best group
(n = 27, 18.5 %), according to their overall survival (Continued)
Temsirolimus 3 (4.5) 0 0
RECIST response <0.001
CR 0 4 (9.1) 3 (15.0)
PR 9 (20.0) 19 (43.2) 9 (45.0)
SD 11 (24.4) 14 (31.8) 8 (40.0)
PD 25 (55.6) 7 (15.9) 0
Laboratory findings
Leukocytosis/Leucopenia 19/1 (28.4/1.6) 4/2 (8.9/4.4) 2/1(7.4/3.7) 0.030
Anemia 51 (76.4) 17 (37.8) 8 (29.6) <0.001
Thrombocytosis/penia 14/2(20.9/3.0) 4/2 (8.9/4.4) 0/0 0.041
Neutrophilia/penia 18/0 (26.9/0) 2/1 (4.4/2.2) 2/1(7.4/3.7) 0.002
Lymphocytosis/penia 1/37 (1.5/55.2) 4/4 (8.9/8.9) 3/1 (11.1/3.7) <0.001
Hyper/hypocalcemia 5/11 (7.4/16.4) 1/2 (2.2/4.4) 0/1 (0/3.7) 0.077
Hypoalbuminemia 12(17.9) 0 0 0.002
LDH elevated 10 (14.9) 2(4.4) 0 0.051
Neutrophil percent high/low 16/1 (23.9/1.5) 0/8(0/17.8) 1/6 (3.7/22.2) <0.001
PFS (mo.) 2.7 (1–9.3) 9.5 (1–28.3) 12.2 (1–68.4) <0.001
OS (mo.) 5.5 (0.3–11.6) 21.6 (12.1–35.7) 63.1 (36.6–88.4) <0.001
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Fig. 1 The Kaplan-Meier curves for (a) progression-free survival (PFS) and (b) overall survival (OS) among the control group and the groups with
the worst and best responses to first-line targeted therapy
Table 3 Predictive factors for progression-free survival after comparing the expected group and the group with the best response
to therapy
Univariate Multivariate
MSKCC risk patients Heng risk patients
Variables OR P-value 95 % CI HR P-value 95 % CI HR P-value 95 % CI
Heng Intermediate risk group 0.25 0.019 0.08–0.8 0.32 0.083 0.09–1.16
Poor 0.09 0.111 0.01–1.76 0.25 0.414 0.01–7.0
Nx 7.31 0.012 1.56–34.33 7.15 0.016 1.43–35.67 3.90 0.076 0.87–17.56
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WG (all, p < 0.05). In this context, several retrospective
studies have reported that nephrectomy provides benefits
for PFS and OS in mRCC by reducing the tumor burden,
although there is debate regarding whether this benefit is
observed for all patients with mRCC. Thus, the results from
two ongoing prospective randomized phase 3 studies may
provide definitive data regarding nephrectomy’s efficacy in
mRCC that is treated using presurgical or postsurgical TT
[22–24]. Nevertheless, the prognostic benefit of nephrec-
tomy during the TT era has generally been positive, as it
likely removes a large proportion of the tumor burden and
facilitates better responses to TT. In the present study, we
found that nephrectomy provided a benefit in 47.6 % of BG
patients with favorable-risk features, although this benefit
was not significant in the multivariate analysis. In addition,
anemia indicated a poor general condition that resembled
paraneoplastic syndrome in mRCC, although anemia is
known to be a marker for poor inflammatory and immune-
related outcomes [8, 9, 25]. Furthermore, the Heng (or
IMDC) prognostic model and the MSKCC model include
anemia as a poor prognostic factor in their criteria for both
PFS and OS [26].
The present study also revealed several significant nega-
tive prognostic markers for OS. In the WG, older age (HR:
1.05), decreased hemoglobin (HR: 4.13), lymphocytopenia
(HR: 4.76), synchronous metastatic state (HR: 3.52), and a
disease-free interval of <1 year were significantly associated
with a reduced OS. In the BG, a disease-free interval of
<1 year (HR: 0.23), the MSKCC intermediate-risk group
(HR: 0.12), and the MSKCC poor-risk group (HR 0.004)
were associated with a prolonged OS (all, p < 0.05). Previ-
ous studies have reported that age is an important prognos-
tic factor for localized RCC, as patients who exhibited late
relapse and survival of >5 years beyond expectations were
significantly younger, compared to patients who experience
early relapse (3 months to 5 years after nephrectomy [27].
Furthermore, patients with RCC who are <40 years old
generally have less aggressive tumor features and better
survival outcomes [27–29]. Therefore, several studies have
suggested that follow-up protocols for younger patients
with RCC should be adjusted to include a longer follow-up,
as these patients generally experience later relapse [27–29].
Similar to anemia, lymphocytopenia was associated with
shortened OS in the present study. In this context, lym-
phocytes play key roles in tumor suppression, which in-
clude inducing cytotoxic cell death and the production of
cytokines in cancer cells. Therefore, lymphocytopenia may
indicate an impaired antitumor response, and explain the
poor prognosis for patients with mRCC [30, 31]. However,
the calcium was not significant prognostic factor in any
comparisions among BG, WG vs. CG (Tables 3, 4 and 5).
The reason for insignificant prognostic role of hypercalce-
mia like other Heng and MSKCC prognostic models was
estimated by the small numbers of hypercalcemia in this
study (4.1 %) similar to that of our previously publishing
papers (9.4 %) with sunitinib study [32] that the hypercal-
cemia was not significant either.
In previous studies of various malignancies (including
mRCC), the presence of synchronous or metachronous
metastasis (based on the time between the diagnoses of
the primary and secondary tumor) was a negative prog-
nostic factor for OS. For example, Kwack et al. demon-
strated that the time to metastasis and the number of
metastases were important prognostic factors for mRCC
during the immunotherapy era [29]. Furthermore, the
International Metastatic Renal Cell Carcinoma Database
Table 4 Predictive factors for overall survival after comparing the expected group and the group with the best response to therapy
Univariate Multivariate
MSKCC risk patients Heng risk patients
Variables OR P-value 95 % CI HR P-value 95 % CI HR P-value 95 % CI
MSKCC Intermediate 0.12 0.001 0.03–0.44 0.12 0.003 0.03–0.49
Poor 0.04 0.040 0.01–0.86 0.04 0.041 0.01–0.87
DFI < 1 year 0.22 0.003 0.08–176.29 0.23 0.013 0.07–0.73
Table 5 Predictive factors for progression-free survival after comparing the expected group and the group with the worst response
to therapy
Univariate Multivariate
MSKCC risk patients Heng risk patients
Variables OR P-value 95 % CI HR P-value 95 % CI HR P-value 95 % CI
Hemoglobin low 3.29 0.003 1.49–7.27 3.25 0.006 1.41–7.52 2.87 0.014 1.23–6.66
Platelet high 1.75 0.288 0.62–4.91
low 1.11 0.916 0.15–8.24
Lymphocyte high 0.56 0.503 0.1–3.08 0.26 0.242 0.03–2.47
Low 2.69 0.016 1.2–6.02 2.05 0.098 0.88–4.78
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Consortium also demonstrated that an increased metastatic
tumor burden at the initial therapy was associated with
worst OS among all patients with mRCC, and that bone
and liver metastases were more frequent in the groups with
poor-risk features [26]. Although we did not observe signifi-
cant differences in the baseline metastatic bone or liver le-
sions between the three groups, bone and liver metastases
were more common in the WG (liver: 26.9 %, bone:
38.6 %), compared to the EG (liver: 12.2 %, bone: 34.0 %)
and the BG (liver: 4.5 %, bone: 23.7 %) (all, p > 0.05).
This study included several limitations that warrant con-
sideration. First, the retrospective design and small sample
size are prone to well-known biases, and larger prospective
studies should be performed to validate our findings. Sec-
ond, we did not perform any histological analyses, and add-
itional analysis of RCC specimens from patients in the BG
and WG might have provided histopathological data re-
garding prognostic biomarkers. Lastly, other existing clin-
ical, political, and economic confounding factors influenced
on the prognosis of mRCC during 8-year period of follow-
up were not dealt in this study. The improving care system
in nutritional, pain, and symptomatic therapeutic fields;
introduction of new various curative and palliative strat-
egies such as radiotherapy and metastatectomy, and widen-
ing coverage of insurance system on mRCC were the most
affecting factors on improvement of prognoses in mRCC,
which should be discussed in future studies. Nevertheless,
our study identified several factors that were associated
with unexpectedly prolonged or shortened survival out-
comes after first-line TT treatment, by comparing the BG
and WG to the EG. Our findings may provide clinicians
with objective markers to identify candidates that are most
and least likely to benefit from TTs. Furthermore, our find-
ings may be useful for developing additional prognostic
models or helping previous models to potentiate their ac-
curacy of prognostic predictability and therapeutic plans
that accurately predict patients’ clinical outcomes in the TT
era. For example, the nephrectomy, the presence of syn-
chronous metastasis, age, and lymphocyte level might be
also helpful in the MSKCC, Heng model to potentiate its
predictability in mRCC treated with first line TT. This
study comprised of 46 % patients who had not received
nephrectomy, whereas previous Heng criteria comprised of
almost all nephrectomized patients that some discrepancies
existed when evaluating the non-nephrectomized patients’
prognoses. Therefore, some additionally useful information
of non-nephrectomized patients’ prognoses would be ob-
tained in this study.
Conclusion
The present study identified several significant predictive
factors that were associated with unexpectedly pro-
longed and shortened survival outcomes after first-line
TT treatment in patients with mRCC. However, a larger
prospective study is needed to validate these factors.
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